On May 21, 2026 Researchers from City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, reported it will present new findings at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, where the cancer center will showcase 49 abstracts spanning solid tumors and blood cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year’s research, to be presented in Chicago from May 29 to June 2, reflects growing efforts to tailor cancer treatment based on tumor biology, prior therapies and patient-specific factors that influence response.
"Cancer care is entering a new phase where understanding the biology of each patient’s disease is just as important as the treatment itself," said Marcel van den Brink, M.D., Ph.D., City of Hope chief physician executive. "The research we are presenting at ASCO (Free ASCO Whitepaper) demonstrates how precision medicine is becoming a reality across cancer types, and how we can use that insight to deliver smarter therapies, improve outcomes and move the field forward."
City of Hope featured oral presentations
4519: Gut microbiome patterns linked to response to immunotherapy in advanced kidney cancer
7007: Targeted antibody combination shows improved outcomes in patients with relapsed large B-cell lymphoma (SUNMO study subgroup analysis)
4015: Experimental therapy targeting a key cancer growth pathway in advanced liver cancer
5014: First-in-human study of a novel targeted therapy for advanced prostate cancer
Microbiome insights may help predict immunotherapy benefit in kidney cancer
City of Hope researchers report that gut microbiome composition may influence how patients respond to immunotherapy combinations in metastatic renal cell carcinoma, pointing to a potential biomarker that could help guide treatment selection in the future.
The microbiome is a rising focus at City of Hope, highlighted by a recent symposium that convened federal health leaders and top cancer centers to accelerate progress in the field.
The study findings come from a combined analysis of two randomized phase 1 trials evaluating standard-of-care immune checkpoint inhibitor regimens with or without the addition of CBM5881, a live biotherapeutic designed to modulate the gut microbiome. The trials enrolled treatment-naïve patients with metastatic disease who received either nivolumab plus ipilimumab or nivolumab plus cabozantinib, reflecting commonly used immunotherapy-based frontline options.
Across the combined dataset, patients who received CBM588 in addition to immunotherapy achieved an objective response rate of 66.7%, compared with 20% among those receiving standard therapy alone. Median progression-free survival improved to 32.1 months with the combination versus 3.7 months with standard treatment.
Researchers also used a metagenomic measure called TOPOSCORE to assess gut imbalance and found that patients with a more disrupted microbiome saw the greatest benefit. In this subgroup, progression-free survival increased from 2.8 months to 24.9 months with the addition of CBM588. The association between microbiome profile and treatment response was particularly evident in patients who received nivolumab plus ipilimumab, suggesting that the microbiome may interact differently depending on the immunotherapy backbone.
The new data support a growing body of research linking the gut microbiome to immune response.
"These findings suggest the microbiome may play a direct role in shaping immunotherapy outcomes," said Rahul Winayak, M.D., postdoctoral fellow at City of Hope. "If validated in larger studies, this approach could help guide treatment decisions and improve outcomes for patients with kidney cancer."
A randomized phase 3 trial is underway to further evaluate this strategy.
Bispecific antibody combination improves outcomes for patients with lymphoma, including in earlier lines of therapy
Updated data from the phase 3 SUNMO trial continue to show that the combination of mosunetuzumab, a bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate, improves outcomes for patients with relapsed or refractory large B-cell lymphoma who are not eligible for autologous stem cell transplant.
The study randomized patients to receive the combination regimen or standard chemotherapy with rituximab, gemcitabine and oxaliplatin. With a median follow-up of more than two years, the combination demonstrated an objective response rate of 70.3%, compared with 40.0% for standard therapy, along with a significant reduction in the risk of disease progression.
A key focus of this updated analysis was outcomes by line of therapy. Among patients who received treatment in the second-line setting, the combination produced higher response rates, deeper remissions and longer durations of response compared with both later-line patients and those who received chemotherapy. Median progression-free survival and duration of complete response were not reached in several subgroups, underscoring the durability of benefit.
The safety profile remained stable with longer follow-up, with low rates of higher-grade cytokine release syndrome and no observed neurotoxicity. These findings support use of this novel regimen in patients who are unable to tolerate aggressive chemotherapy.
"These results support the growing role of bispecific antibody-based combinations as an alternative to traditional chemotherapy," said Elizabeth Budde2, M.D., Ph.D., executive medical director of the Enterprise Immune Effector Cell Program at City of Hope. "We are especially encouraged by the durability of responses in earlier lines of therapy, where improving long-term outcomes is critical for every patient."
New therapy targeting a key cancer growth pathway shows promise in advanced liver cancer
City of Hope investigators are evaluating tegavivint, a first-in-class small-molecule inhibitor that targets the Wnt/β-catenin signaling pathway, a key driver in many liver cancers that have historically been difficult to treat.
The ongoing phase 1/2 study includes patients with advanced hepatocellular carcinoma who have received at least one prior line of systemic therapy and have disease that cannot be treated with surgery or localized therapies.
Among patients with Wnt pathway mutations detected with molecular profiling and treated within the recommended dose range, the therapy demonstrated clinical activity, with an objective response rate of 22%, disease control rate of 89% and median progression-free survival of eight months in patients treated earlier in their disease course.
Importantly, the study showed evidence of target engagement, including reductions in alpha-fetoprotein levels and changes in Wnt pathway circulating tumor DNA allele frequency. These findings suggest that the drug is affecting the intended biological pathway, a key challenge in prior efforts to target Wnt signaling.
"Targeting the Wnt pathway has long been a major challenge in oncology, but these data suggest we may finally be making progress," said Daneng Li, M.D., gastrointestinal medical oncologist at City of Hope. "With further validation, this approach could meaningfully expand treatment options and provide a potential targeted therapy approach to improve outcomes for patients with advanced liver cancer."
First-in-human study shows early activity for novel prostate cancer therapy
City of Hope researchers are presenting early results from a first-in-human study of ABBV-969, a dual-targeting antibody-drug conjugate that binds PSMA and STEAP1, two proteins commonly found in advanced prostate cancer. The therapy is designed to deliver a potent anti-cancer agent directly to tumor cells expressing PSMA and/or STEAP1 antigens.
The phase 1 study enrolled patients with metastatic castration-resistant prostate cancer who had received multiple prior lines of therapy, including androgen receptor pathway inhibitors and taxane-based chemotherapy to stop cell division. Patients were treated across a range of dose levels to evaluate safety, pharmacokinetics and preliminary efficacy.
Among patients with measurable disease, the therapy achieved an objective response rate of 45%, with responses observed across multiple dose levels starting at 3 mg/kg. Reductions in prostate-specific antigen (PSA) levels were also common, with 67% of patients achieving a PSA50 response and 28% achieving deeper PSA declines of 90% or greater.
The study assessed a range of doses and dose optimization is ongoing. The study also demonstrated a manageable safety profile. The most common higher-grade adverse events were hematologic, including anemia, which were generally reversible and consistent with the drug’s mechanism of action.
"We are seeing early signals that this targeted approach can deliver meaningful responses, even in heavily pretreated patients," said Tanya Dorff3, M.D., F.A.S.C.O., genitourinary medical oncologist at City of Hope. "The next step will be to better understand how to position this therapy to further improve outcomes."
(Press release, City of Hope, MAY 21, 2026, View Source [SID1234665973])